THYROCAREThyrocare Tech.

₹1356.5-1.80%

Market Cap

₹7,204.45 Cr

Stock P/E

56.40

ROCE

27.25%

ROE

17.04%

Book Value

₹100.70

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Franchisee base is at its highest ever with a steady growth in the franchisee base over the last two years.
•
Thyrocare became India’s first and only 100% NABL accredited national laboratory chain, underscoring quality leadership.

NEGATIVES

•
Margin pressures from recent acquisitions and geographic expansions weighed on quarterly performance.
•
Franchisee churn exists; only net additions are reported, masking higher churn levels.

Peers Summary

Sector Leader

Thyrocare Technologies Ltd. stands out among its peers with solid revenue growth and low debt levels while maintaining a competitive position in profitability metrics. However, it is relatively overvalued compared to some peers, making it a potential candidate for cautious investment.

Key Points

• Thyrocare shows strong revenue growth at 20.19% YoY and low debt equity ratio of 0.0413.
• Max Healthcare has the highest PE ratio of 163.58, indicating potential overvaluation.
• Aster DM Healthcare is the best value pick with a PE of 5.05 and decent profitability metrics.

Top Performers

Narayana Hrudayalaya Ltd.

Highest ROE at 24.27% and solid EPS growth.

Thyrocare Technologies Ltd.

Strong revenue growth at 20.19% YoY and low debt levels.

Global Health Ltd.

Good balance of growth and profitability with a solid ROE of 15.31%.

Explore

Watchlists

Command Palette